This SLN-based CRISPR-Cas9 gene-editing system knocked out HuR, an RNA binding protein whose overexpression upregulates cancer-related transcripts of survival and resistance in various cancers, thus enhancing the antitumor efficacy of epirubicin chemotherapy. This evidence concerns the gene ELAVL1 and cancer.